UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy

ACS nano, 2017-11, Vol.11 (11), p.11127-11134

2017

Volltextzugriff (PDF)

Increased RNA Editing May Provide a Source for Autoantigens in Systemic Lupus Erythematosus

Cell reports (Cambridge), 2018-04, Vol.23 (1), p.50-57

2018

Volltextzugriff (PDF)

In-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking Applications

Scientific reports, 2015-10, Vol.5 (1), p.15400-15400, Article 15400

2015

Volltextzugriff (PDF)

Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes

Journal of Immunology, 2006-11, Vol.177 (9), p.6548-6559

2006

Volltextzugriff (PDF)

Genetically engineering glycolysis in T cells increases their antitumor function

Journal for immunotherapy of cancer, 2024-07, Vol.12 (7), p.e008434

2024

Volltextzugriff (PDF)

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

Nature (London), 2019-07, Vol.571 (7764), p.265-269

2019

Volltextzugriff (PDF)

Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T‑Cells in Vivo with Gold Nanoparticles and CT Imaging

ACS nano, 2015-06, Vol.9 (6), p.6363-6372

2015

Volltextzugriff (PDF)

Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.135-9, Article 135

2019

Volltextzugriff (PDF)

Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity

The Journal of immunology (1950), 2013-10, Vol.191 (8), p.4121-4129

2013

Volltextzugriff (PDF)

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

The Journal of clinical investigation, 2015-10, Vol.125 (10), p.3981-3991

2015

Volltextzugriff (PDF)

T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer

Advanced drug delivery reviews, 2019-02, Vol.141, p.23-40

2019

Volltextzugriff (PDF)

Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Clinical cancer research, 2022-12, Vol.28 (23), p.5156-5166

2022

Volltextzugriff (PDF)

Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells

The Journal of immunology (1950), 2012-02, Vol.188 (4), p.1708-1716

2012

Volltextzugriff (PDF)

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

Cancer research (Chicago, Ill.), 2006-09, Vol.66 (17), p.8878-8886

2006

Volltextzugriff (PDF)

Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity

The Journal of immunology (1950), 2012-06, Vol.188 (11), p.5538-5546

2012

Volltextzugriff (PDF)

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond

Cancer research (Chicago, Ill.), 2007-04, Vol.67 (8), p.3898-3903

2007

Volltextzugriff (PDF)

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma

The Journal of clinical investigation, 2021-10, Vol.131 (20)

2021

Volltextzugriff (PDF)

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System

Molecular therapy, 2016-06, Vol.24 (6), p.1078-1089

2016

Volltextzugriff (PDF)

A novel lncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity

Oncotarget, 2017-04, Vol.8 (14), p.23775-23786

2017

Volltextzugriff (PDF)

Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells

Cancer immunology research, 2024-10, Vol.12 (10), p.1380-1391

2024

Volltextzugriff (PDF)

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

Cancer immunology research, 2016-08, Vol.4 (8), p.669-678

2016

Volltextzugriff (PDF)

Genetically modulating T-cell function to target cancer

Seminars in cancer biology, 2012-02, Vol.22 (1), p.14-22

2012

Volltextzugriff (PDF)

Enhanced antitumor activity mediated by human 4‐1BB‐engineered T cells

International journal of cancer, 2013-12, Vol.133 (12), p.2903-2913

2013

Volltextzugriff (PDF)

Selected murine residues endow human TCR with enhanced tumor recognition

The Journal of immunology (1950), 2010-06, Vol.184 (11), p.6232-6241

2010

Volltextzugriff (PDF)

High Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation

Molecular therapy, 2006-01, Vol.13 (1), p.151-159

2006

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(38)

Sprache

Englisch
(37)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(29)
Animals
(20)
Mice
(18)
T-Lymphocytes - Immunology
(17)
Oncology
(13)
Cell Line, Tumor
(12)
Immunology
(12)
Receptors, Antigen, T-Cell - Genetics
(12)
Tumors
(10)
Biological And Medical Sciences
(9)
Immunotherapy
(9)
Lymphocytes
(9)
Medical Sciences
(9)
Melanoma
(9)
Melanoma - Immunology
(9)
Cell Proliferation
(8)
Neoplasms - Immunology
(8)
Antigens
(7)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy

Increased RNA Editing May Provide a Source for Autoantigens in Systemic Lupus Erythematosus

In-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking Applications

Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes

Genetically engineering glycolysis in T cells increases their antitumor function

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T‑Cells in Vivo with Gold Nanoparticles and CT Imaging

Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides

Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer

Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System

A novel lncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity

Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

Genetically modulating T-cell function to target cancer

Enhanced antitumor activity mediated by human 4‐1BB‐engineered T cells

Selected murine residues endow human TCR with enhanced tumor recognition

High Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation

Aktive Filter

Suchergebnisse filtern